WAUKEGAN, Ill.--(BUSINESS WIRE)--NEOPHARM, Inc. (NASDAQ:NEOL) today announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere® (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy.
